Last reviewed · How we verify
NMRC-M3V-Ad-PfCA
At a glance
| Generic name | NMRC-M3V-Ad-PfCA |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1 (PHASE1, PHASE2)
- A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMRC-M3V-Ad-PfCA CI brief — competitive landscape report
- NMRC-M3V-Ad-PfCA updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI